High resolution, accurate mass LC-MS/MS technology combines with mass defect filtering software to improve the speed and efficiency of early-stage drug discovery and late-stage drug development.
SEM-based systems can give researchers a better look at sub-micron pharmaceutical particles.
In Depth: GPCR AnalysisMeet the scientists of Drug Discovery & Development magazine's GPCR Roundtable.
Although human-to-human clones (human clones) and human-to-animal clones (hybrids) appear similar, the pattern of reprogramming of the donor human cell is dramatically different.
Bailout. Blagojevich. Foreclosure. Furlough. There has not been a lot of “happy news” lately. Even peanut butter has had negative press.
In Depth: GPCR AnalysisCompanies are beginning to develop imaging technologies to study GPCRs.
In Depth: GPCR AnalysisGenetic or genomic approaches are used to validate targets of potential therapeutic interest. Find out how genomic approaches are used in identigying GPCR targets.
In Depth: GPCR AnalysisDrug Discovery & Development magazine conducted a roundtable discussion with industry scientists to answer questions about GPCR. Below are the answers to a question related to crystallizing GPCR.
In Depth: GPCR AnalysisRecombinant systems help do primary screens of GPCRs. Find out why recombinant systems are helpful in GPCR screening.
Millipore Corporation announced that it has entered into an agreement to acquire Guava Technologies.
In Depth: GPCR Analysis Cellular location, function in physiology, and relevance in disease, are among the many factors that make GPCRs druggable targets.
Ablynx announced it has successfully generated Nanobodies against several GPCR receptors.
The state known as the nation's medicine chest is bleeding from sweeping job cuts to its high-paying pharmaceutical industry.
A company can’t develop a new drug without animal models.
While no strangers to financial challenges, biotech and pharmaceutical companies are scrambling to find ways to weather the recession.